Indo-MIM은 가난한 사람들을 돕기 위해 노력하고 있으며, 사회 전체를 돕기 위해 연구실 (수집 구역 제외)으로 구성된 “THE CHIVUKULA WING” 2008 년 1 월 전 APJ Abdul Kalam 박사가 출범 한 방갈로 침례 병원 (Venalore Baptist Hospital)의 혈액 은행, 심장 카테 테르 화 실험실 (Cath. Lab), 심장 케어 유닛 및 20 개의 개별 실을 방문했습니다. Dr. Chivukula는 $ 1 소외된 이들에게 저렴한 비용으로 양질의 의료 서비스를 제공하려는 의도와 함께 최첨단 시설을 제공하는 고귀한 이유로 백만 달러.

Chivukula 박사의 개인적인 참여로, 날개의 계획과 건설은 엄숙하게되기까지 18 개월이 걸렸습니다. 21, 438.5 sq. ft.의 면적에 지어졌으며이 윙은 새로운 바이러스 시설을 갖춘 정교한 실험실 서비스를 제공합니다. 면역학 (호르몬 패널), 혈청학 (전염병 (예 : 토치 패널))에 새로운 검사가 도입되었으며 조직 병리학 및 혈액학에 자동화가 도입되었습니다. 2011 년부터이 플로어의 시설에 일부 추가되었습니다 .

동시에 고도의 불임 환경에서 효과적인 수술을 제공하기 위해 설립 된 정형 외과 안과 수술 센터와 함께 우수한 심장학 서비스가 불우한 환자에게 제공되고 있습니다. 병리 조직학의 결장 및 TB 문화 연구소는 올해 시작될 예정이지만, Blood Bank는 이미 2010 년부터 구성 요소 분리를 시작했습니다. 개인 실의 증가는 많은 수의 유료 환자를 인정하는 데에도 도움이되었습니다. 가난한 환자 치료 보조금.

날개가 사회를 위해 병원에서 사용되는 동안, 회사는 또한 병원에서 기금을 설립하고 빈곤 한 환자의 의학적 필요를 돌보는 기금에 월간 기부를합니다. 방갈로르 침례 병원의 관리에 의해 전적으로 관리된다. 가난한 가정에 대한 만족은 회사에 큰 즐거움입니다.

baptist_dr_naveenthomas
“방갈로르 침례 병원 (Bangalore Baptist Hospital, BBH)의 지난 10 년간의 성장을 돌아 보면 고맙게 생각합니다. Krishna Chivukula는 병원의 성장 스토리에 중요한 역할을했습니다. Indo-MIMS의 기부로 Chivukula Wing을 건설 할 수 있었던 것은 2006 년입니다. 이 행사는 병원의 급성장을위한 일련의 단계 중 첫 번째 행사였습니다. Chivukula Wing에는 새로 확장 된 NABL 인정 실험실과 관상 동맥 관리실 (Coronary Care Unit)에 최신 심장 카테터 실험실이 있습니다. Chivukula 윙은 2008 년 1 월 18 일 인도 전 대통령 Abdul Kallam이 출범했습니다.

Chivukula는 가난한 환자 간호 기금에 기부를 계속했습니다. 공립 초등 학교 Hebbal 학생들의 건강 필요 사항은이 기금을 사용하여 검토되었습니다. 상당수의 다른 환자도이 이니셔티브를 통해 도움을받습니다. 재정적 인 개입 외에도, Chivukula는 성장의 여정과 ‘임상 적 우수성’의 길에서 좋은 친구이자 조언자이자 격려 자입니다. Indo-MIMS와 협력 해 주셔서 감사합니다! ”

Dr. Naveen Thomas, Director (CEO) Bangalore Baptist Hospital
By |2008-01-26T09:00:15+05:30January 26, 2008|Uncategorized|Comments Off on [:en]Baptist Hospital[:zh]Baptist Hospital[:tr]Baptist Hastanesi[:pt]Hospital Batista

Share This Story, Choose Your Platform!

FacebookXRedditLinkedInWhatsAppTumblrPinterestVkXingEmail

Related Posts

DRHP-AV

DRHP-AV

Corporate Governance Policies

Corporate Governance Policies

Offer Documents

Offer Documents

Appointment Letters

Appointment Letters

Indo-MIMは貧しい人々を助けるために尽力しており、社会全体を助けるために、同社は実験室からなる「THE CHIVUKULA WING」と呼ばれる新しい区画の設立に全額出資しています（回収区域を除く）。 、血液銀行、心臓カテーテル検査室（Cath.Lab）、心臓病治療室、そして2008年1月にAPJアブドゥル・カラーム前総長が発足したバンガロールバプテスト病院の20の個室。チヴクラ博士は1ドルを寄付した。低コストで貧弱な人々にヘルスケアを提供し、それを買うことができない人々に譲歩的/無料のケアを提供することを意図して、最先端の設備を提供する貴族のための100万人。

チヴクラ博士の個人的な関与により、翼の計画と建設は厳粛になるのに18か月かかりました。 21の区域で造られて、438.5平方フィート、この翼は新しいウイルス学設備が付いている精巧な実験室サービスを有する。免疫学（ホルモンパネル）、血清学（感染症（例：トーチパネル））に新しい検査が導入され、病理組織学および血液学に自動化が導入されています。 。

同時に、高度に滅菌された環境で効果的な手術を提供するために設立された整形外科および眼科用シアターコンプレックスとともに、必要としている患者に優れた心臓学サービスも提供されています。病理組織学の凍結切片と結核カルチャーラボは今年開始される予定ですが、血液銀行は2010年以来すでに成分分離を開始しています。貧弱な患者ケアを助成する。

ウィングは病院で社会の利益のために使用されていますが、同社は病院に基金を設立し、非常に貧しい患者の医療ニーズに対応するために毎月基金に寄付しています。これは完全にバンガロールバプテスト病院の管理によって管理されています。貧しい家族の間での満足は、会社にとって非常に大きな喜びです。

baptist_dr_naveenthomas
「私たちが過去10年間のBangalore Baptist Hospital（BBH）の成長を振り返るのは、心から感謝します。 Krishna Chivukula氏は病院の成長ストーリーで大きな役割を果たしました。 2006年、Indo-MIMSからの多額の寄付を通じて、チヴクラウィングを建造することができました。この出来事は病院の急成長への道を開いた一連のステップの最初のものでした。チブクラウィングには、新しく拡張されたNABL認定ラボラトリーと、最新の心臓カテーテル検査ラボを備えた冠状動脈疾患治療室があります。チヴクラウィングは2008年1月18日にインドの前大統領であるDr. Abdul Kallamによって発足しました。

チヴクラ氏は貧しい患者ケア基金に寄付し続けています。政府小学校ヘブバルの生徒の健康上の必要性は、この基金を使って管理されています。このイニシアチブを通じて、他にも多くの値する患者が助けられています。経済的な関与に加えて、チヴクラ氏は私たちの成長の旅と「臨床の卓越性」への道においても、友人、助言者、そして励ましとなりました。 Indo-MIMSと提携していただきありがとうございます。」

Dr. Naveen Thomas, Director (CEO) Bangalore Baptist Hospital
By |2008-01-26T09:00:15+05:30January 26, 2008|Uncategorized|Comments Off on [:en]Baptist Hospital[:zh]Baptist Hospital[:tr]Baptist Hastanesi[:pt]Hospital Batista

Share This Story, Choose Your Platform!

FacebookXRedditLinkedInWhatsAppTumblrPinterestVkXingEmail

Related Posts

DRHP-AV

DRHP-AV

Corporate Governance Policies

Corporate Governance Policies

Offer Documents

Offer Documents

Appointment Letters

Appointment Letters

white logo

SERVICES

SECTORS WE SERVE

COMPANY INFORMATION

Copyright @ 2024 INDO-MIM | All Rights Reserved

DISCLAIMER – IMPORTANT

PLEASE READ THIS NOTICE CAREFULLY. IT APPLIES TO ALL PERSONS WHO VIEW THIS WEBSITE. THESE MATERIALS ARE NOT DIRECTED AT OR INTENDED TO BE ACCESSED BY PERSONS LOCATED OUTSIDE INDIA. VIEWING THIS INFORMATION MAY NOT BE LAWFUL IN CERTAIN JURISDICTIONS.

YOU SHOULD READ IT IN FULL EACH TIME YOU VISIT THE WEBSITE. BY ACCESSING THIS INFORMATION ON THIS WEBSITE, YOU AGREE TO THE TERMS AND CONDITIONS BELOW, INCLUDING ANY MODIFICATIONS THAT MAY BE MADE TO THEM FROM TIME TO TIME

THE DRAFT RED HERRING PROSPECTUS HAS BEEN MADE AVAILABLE ON OUR WEBSITE TO COMPLY WITH THE SECURITIES AND EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2018, AS AMENDED.

IMPORTANT: You must read and agree with the terms and conditions of the following disclaimer before continuing.

The following disclaimer applies to the draft red herring prospectus of INDO-MIM Limited (the “Company”) dated September 26, 2025 (the “Draft Red Herring Prospectus”) filed with the Securities and Exchange Board of India (“SEBI”), BSE Limited, and the National Stock Exchange of India Limited and hosted on this website in connection with the initial public offering of the equity shares of the Company (the “Offer”).

Access to the Draft Red Herring Prospectus does not constitute a recommendation by the Company, the members of the Syndicate (as defined in the Draft Red Herring Prospectus) or any of their respective affiliates or any other person to subscribe to the Equity Shares offered in the Offer.

The Draft Red Herring Prospectus is directed at, and is intended for distribution to, and use by, residents of India only. The information in this portion of our website, including the Draft Red Herring Prospectus, is not for publication or distribution, directly or indirectly, in or into the United States. No part of the contents of the Draft Red Herring Prospectus shall be copied or duplicated in any form by any means or redistributed.

The Draft Red Herring Prospectus has been hosted on this website as prescribed under Regulation 26(1) of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended. Our Company has taken all necessary steps to ensure that the contents of the Draft Red Herring Prospectus as appearing on this website are identical to the Draft Red Herring Prospectus filed with the SEBI, BSE Limited, and the National Stock Exchange of India Limited. You are reminded that documents transmitted in electronic form may be altered or changed during the process of transmission and consequently, neither the Company nor any of its affiliates, directors, agents, officers, representatives, advisers or employees accepts any liability or responsibility whatsoever in respect of alterations or changes which have taken place during the course of transmission of electronic data.

The Draft Red Herring Prospectus does not constitute an offer to sell or an invitation to subscribe to the securities offered in any jurisdiction to any person to whom it is unlawful to make an offer or invitation in such jurisdiction and is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where (a) distribution or use of such information would be contrary to law or regulation; or (b) the Company or any of its affiliates would by virtue of such distribution become subject to new or additional registration, licensing or other regulatory requirements. The securities described in the Draft Red Herring Prospectus have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any other applicable law of the United States and, unless so registered, may not be offered or sold within the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable state securities laws. Accordingly, the securities described in the Draft Red Herring Prospectus are being offered and sold (a) in the United States only to persons reasonably believed to be “qualified institutional buyers” (as defined in Rule 144A under the U.S. Securities Act) pursuant to the private placement exemption set out in Section 4(a) of the U.S. Securities Act, and (b) outside the United States in “offshore transactions” as defined in and in compliance with Regulation S under the U.S. Securities Act and the applicable laws of the jurisdictions where those offers and sales are made. For the avoidance of doubt, the term “U.S. QIBs” does not refer to a category of institutional investors defined under applicable Indian regulations and referred to in this Draft Red Herring Prospectus as “QIBs”. There will be no public offering of such securities in the United States.

Any person into whose possession the Draft Red Herring Prospectus comes is required to inform himself or herself about and to observe any such restrictions. Neither the Company nor any of its affiliates is soliciting any action based on the Draft Red Herring Prospectus, and it should not be construed as an offer to sell or the solicitation of an offer to buy any securities. Potential investors should not rely on the Draft Red Herring Prospectus for any investment decision.

Any decision on whether to invest in the securities described in the Draft Red Herring Prospectus may only be made after a Red Herring Prospectus has been filed with the Registrar of Companies, Karnataka at Bengaluru and the SEBI and must be made solely on the basis of such Red Herring Prospectus, as there may be material changes in the Red Herring Prospectus compared to the Draft Red Herring Prospectus. Invitations to subscribe to or purchase the equity shares in the Offer will be made only pursuant to the Red Herring Prospectus if the recipient is in India or the preliminary offering memorandum for the Offer, which comprises the Red Herring Prospectus and the preliminary international wrap for the Offer, if the recipient is outside India. No person outside India is eligible to Bid for equity shares in the Offer unless that person has received the preliminary offering memorandum for the Offer, which shall contain the selling restrictions for the Offer outside India.

Any potential investor should note that investment in equity shares involves a high degree of risk and for details relating to such risk, please see the section titled “Risk Factors” of the Draft Red Herring Prospectus. The Offer shall be made only pursuant to the Red Herring Prospectus, when available. Potential investors should also refer to the Red Herring Prospectus which will be filed with the Registrar of Companies, Karnataka at Bengaluru, and SEBI in the future, including the section titled “Risk Factors.”

Neither the Company nor any of its affiliates, directors, agents, officers, representatives, advisers, or employees will be responsible for any loss or damage that could result from interception and interpretation by any third parties of any information being made available to you through this website. The Company and its affiliates cannot and do not guarantee the accuracy, timeliness or completeness of the information being made available to you in the Draft Red Herring Prospectus beyond the date of the Draft Red Herring Prospectus. The information contained in the Draft Red Herring Prospectus may not be updated since its original publication date and may not reflect the latest updates. The Company and its affiliates will not be responsible for any loss to any person or entity caused by any shortcoming, defect or inaccuracy which may have inadvertently or otherwise crept into the website. Neither the Company, any of its affiliates nor their directors, officers and employees will be liable or have any responsibility of any kind for any loss or damage that you incur in the event of any failure or disruption of this website, or resulting from the act or omission of any other party involved in making this website or the data contained therein available to you, or from any other cause relating to your access to, inability to access, or use of the website or these materials.

If you are not permitted to view the materials on this website or are in any doubt as to whether you are permitted to view these materials, please exit this webpage.

To access this information, you must confirm by pressing on the button marked "I Confirm" that, at the time of access you are located and resident in India. If you cannot make this confirmation, you must press the button marked "I Do Not Confirm".

The documentation contained in these pages is posted solely to comply with Indian legal and regulatory requirements. Making the information contained herein available in electronic format does not constitute an offer to sell, the solicitation of an offer to buy, or a recommendation to buy or sell securities of the Company in the United States or in any other jurisdiction, including without limitation, India.

Current step:Step 1
Step 2
Go to Top